Acorda Therapeutics Inc.
- Consumer Products
- Latest 34.84
- Currency US$
- Change -0.11
- Percent Change -0.315 %
- Volume 291,793
- Wed Jun 19, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||May 2||$0.18||Aug 6||$0.10|
12 months ended Jun 19, 2013.
A look at major corporate events and financial announcements that are coming up.
About the Company
Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.
Head Office420 SAW MILL RIVER ROAD